Matterhorn Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Matterhorn Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-17,941	Closed	-$3.11M	–	59
2015 Q1	$3.11M	Buy	17,941 +262	+1%	+$47.4K	1.39%	47
2014 Q4	$3.27M	Buy	17,679 +4,867	+38%	+$902K	1.53%	41
2014 Q3	$2.13M	Sell	12,812 -1,653	-11%	-$271K	0.95%	53
2014 Q2	$2.26M	Sell	14,465 -155	-1%	-$24.5K	1%	54
2014 Q1	$2.19M	Sell	14,620 -504	-3%	-$80.1K	1.01%	53
2013 Q4	$2.01M	Buy	15,124 +464	+3%	+$55.7K	0.93%	54
2013 Q3	$1.7M	Buy	14,660 +75	+0.5%	+$8.23K	0.85%	53
2013 Q2	$1.34M	Buy	+14,585	New	+$1.41M	0.74%	52

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Matterhorn Capital Management's ALXN Position: Q2 2015 in Review

Matterhorn Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2015, closing a stake of 17,941 shares — an estimated $3.11M sold.

Matterhorn Capital Management first reported a position in ALXN in Q2 2013 and held it in 8 quarters. The position peaked at $3.27M in Q4 2014. 547 funds tracked by Wall St. Rank hold ALXN as of Q2 2015.

Matterhorn Capital Management reported no remaining Alexion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Matterhorn Capital Management sold 17,941 Alexion Pharmaceuticals shares in Q2 2015, an estimated $3.11M.
Matterhorn Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 8 quarters.
Matterhorn Capital Management's Alexion Pharmaceuticals position peaked at $3.27M in Q4 2014.
547 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2015.

Based on Matterhorn Capital Management's 13F filing for Q2 2015, filed 3 Aug 2015.